Lee Ka Chiu John: The Hong Kong SAR Government hopes to set up a food and drug administration in the future. Lee Ka Chiu John, Chief Executive of the Hong Kong Special Administrative Region (HKSAR) said today (11th) that the SAR Government hopes to set up a food and drug administration in the long run to give full play to the advantages of clinical trials with the Mainland.Facewall Intelligence has received a new round of financing of several hundred million yuan. Recently, Facewall Intelligence has completed a new round of financing of several hundred million yuan. This round of financing was jointly led by Loongson Venture Capital, Dinghui Baifu, Zhongguancun Science City Fund and Safran Investment Fund, and Beijing Artificial Intelligence Industry Investment Fund and Zero2IPO followed suit.The decline of treasury bond futures expanded, with the 30-year main contract falling by 0.50%, the 30-year main contract falling by 0.50%, the 10-year main contract falling by 0.18%, the 5-year main contract falling by 0.12% and the 2-year main contract falling by 0.05%.
The speaker of South Korea's National Assembly called for an investigation into martial law.The AI application steering wheel went down at the beginning, Huayang Lianzhong fell, the AI application steering wheel went down at the beginning, Huayang Lianzhong fell, Fengyuzhu, Fushi Holdings, Wanxing Technology, Jincai Internet, Tianyu Digital Branch and so on followed.Shangtang Technology completed the placement of a number of international funds, long-term funds and existing shareholders of about HK$ 2.8 billion. For the news that Shang Tang announced today that it plans to place 1.865 billion shares and raise HK$ 2.787 billion, the reporter learned that a number of internationally renowned funds, long-term funds and existing shareholders will participate, and the funds raised will be used to support the company's core business development, including building an industry AI cloud, upgrading the scale of Shang Tang's large-scale devices, supporting generative artificial intelligence, including large-scale model research and product development, and (science and technology innovation board Daily)
How to "bargain" the price difference of Chinese patent medicines? According to CCTV news, the National Medical Insurance Bureau responded that the price of proprietary Chinese medicines is affected by many factors, including the price of medicinal materials, production technology and brand value, in view of the large price difference of proprietary Chinese medicines and the problem of "bargaining". Centralized purchasing effectively squeezes the inflated price of drugs and improves the efficiency of capital use through market-oriented bidding and price-volume linkage. At the same time, the medical insurance bureau will strengthen monitoring and supervision to ensure the quality and supply of drugs and protect the rights and interests of patients.The change in the concept of computing power leasing has increased the daily limit of Yakang shares and Chengdi Xiangjiang, and the concept of computing power leasing has increased. Both Yakang shares and Chengdi Xiangjiang have daily limit, and Runze Technology, Yunsai Zhilian, Tongniu Information and Kehua Data have followed suit.The newly established technology companies such as Doushen Education include a number of AI businesses. The enterprise search APP shows that recently, Shenzhen Doushen Bilingual Times Technology Co., Ltd. was established, with Hu Xiaokang as the legal representative and a registered capital of 1 million yuan. Its business scope includes artificial intelligence application software development, artificial intelligence basic resources and technology platform, artificial intelligence basic software development, artificial intelligence general application system and artificial intelligence hardware sales. Enterprise investigation shows that the company is jointly owned by Doushen Times Technology Development (Beijing) Co., Ltd. and Shenzhen Heyun Education Technology Co., Ltd., a subsidiary of Doushen Education.
Strategy guide
Strategy guide
Strategy guide 12-13